Join the GenScript Biotech Global Forum in London to Navigate the Future of Cell and Gene Therapies.

PISCATAWAY, N.J., Nov. 13, 2024 /PRNewswire/ -- The global cell and gene therapy (CGT) industry is poised for remarkable growth, driven by significant advances in life sciences and robust investments from capital markets. To strengthen this vital sector, GenScript is bringing together leading scientists, industry experts, investors, and regulatory authorities at the GenScript Biotech Global Forum. This series of conferences aims to address key industrial trends in cell therapy and gene therapy.

For more information, please visit the forum website.
Scan QR code or click the link to register: https://bit.ly/477v0pa
(Register using code GSOM to reserve your free pass.)
 

In this November 20, GenScript Biotech Global Forum will take place in London during the Jefferies London Healthcare Conference. This year's forum will explore the theme "Unlock the Full Potential of Cell and Gene Therapies." This event aims to foster collaboration among industry leaders while tackling the challenges and opportunities in the CGT landscape.

Highlights of the Agenda Include

Navigating Challenges: Insights into the Future of CGT and Multiple Cell Therapy Technologies in Development

In recent years, cell and gene therapy has become a key player in biopharmaceuticals, with a growing number of approvals annually. CAR-T therapies are the most advanced, while innovations have led to a wider range of cell therapies, including CAR-NK, CAR-M, and TIL, addressing various challenging diseases.

However, the diverse landscape of new therapies and technologies presents numerous challenges. The forum will feature keynote speeches from prominent figures in cell and gene therapy, including Dr. James M. Wilson, President and CEO of Gemma Biotherapeutics; Dr. Miguel Forte, President of the International Society for Cell & Gene Therapy (ISCT) and CEO of Kiji Therapeutics, and Tom Whitehead, co-founder of the Emily Whitehead Foundation will also give a speech to share the life-saving stories of CAR-T therapy.

In-Depth Discussion on Gene Therapy, mRNA Vaccines and the CMC Challenges in Developing and Manufacturing CGT Product

The development of gene therapy and mRNA vaccine technologies has been transformative, particularly during the COVID-19 pandemic, and holds immense promise for treating rare diseases and genetic disorders. As advancements in gene editing reshape clinical applications, emerging innovations in gene therapy and mRNA vaccines are poised to revolutionize medicine. However, the transition of these technologies from research and development to clinical application brings significant challenges. Throughout the development and production of cell and gene therapies, issues related to CMC are prevalent. The quality of raw materials and the stability of supply chains directly impact early development, while the complexity and consistency of manufacturing processes, from small-scale trials to large-scale commercialization, remain key obstacles. Further optimization is needed in process scaling and standardization, alongside the ongoing challenge of ensuring product quality and safety in compliance with stringent regulatory standards for successful market entry. The forum will explore these challenges, as well as emerging market trends and future opportunities for innovation, through in-depth panel discussions.

Exploring the Investment Potential of CGT: A Future Outlook

The cell and gene therapy (CGT) industry faces challenges in investment returns due to high development costs, regulatory hurdles, and manufacturing complexities. However, significant opportunities exist in gene editing and cell-based therapies, which offer promise for treating various diseases. Attracting funding requires understanding the potential impact of these therapies and their path to commercialization. This forum will feature a fireside chat with investment insights, helping attendees explore CGT's potential and how to secure long-term returns as therapies progress toward commercialization.

For more information, please visit the forum website.
Scan QR code or click the link to register: https://bit.ly/477v0pa
(Register using code GSOM to reserve your free pass.)
 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Join the GenScript Biotech Global Forum in London to Navigate the Future of Cell and Gene Therapies.

Join the GenScript Biotech Global Forum in London to Navigate the Future of Cell and Gene Therapies.

Join the GenScript Biotech Global Forum in London to Navigate the Future of Cell and Gene Therapies.

Join the GenScript Biotech Global Forum in London to Navigate the Future of Cell and Gene Therapies.

Join the GenScript Biotech Global Forum in London to Navigate the Future of Cell and Gene Therapies.

JAKARTA, Indonesia, Nov. 14, 2024 /PRNewswire/ -- This November, Belgian business management software company Odoo celebrates 1st anniversary of the Indonesian office with esteemed partners and customers like Ismaya, Pertamina Energy Terminal, DORÉ, Dekoruma, Abuba Steak, Perum Bulog and Arista Group, to name a few.

With a mission to help more businesses to become digitally organized, the software company started actively developing the Indonesian market five years ago and has reached record-breaking milestones one after another—91.2% average annual growth and a quadrupled 189 active local partners—making Indonesia the best-performing market in APAC for six consecutive years.

The now locally based Odoo Indonesia is confident in extending services and helping businesses of all sizes in the country to digitally transform business management to contribute to optimized workflow efficiency and national economic growth.

To support rapid market expansion, Odoo will base its operations in BSD as the area embodies the start-up environment the Belgian firm always strives for—vibrant & dynamic—a choice affirmed by its sustained success in digital transformation endeavors across Indonesia.

Odoo opens first SEA office in BSD.

From a squad of 3, Odoo Indonesia has expanded into an over 80-strong team. In 2024, it engaged the community at 41 events in major cities, including Medan, Bandung, Surabaya, and Makassar, and around the archipelago in Java, Sumatra, Kalimantan, and Sulawesi, providing countless on-site support. Within a year of opening, the company introduced multiple landmark integrations and regionalized upgrades.

Odoo-Xendit Integration

Integration with Indonesian-based payment solution provider Xendit is made standard in Odoo to facilitate effortless transactions in Indonesia and across Southeast Asia through QRIS, e-Wallets, convenience stores, and other major payment methods in the region.

e-Faktur Submission

To support the Tax Office e-Faktur application, Odoo now collects necessary data to automate documents to assist users in completing the submission process in compliance with local regulations and is in the last stages of integrating with Pajak.io for direct submission from Odoo.

QRIS Features

The team introduced QRIS into the system to maximize ways to receive payments, facilitating a more convenient and localized payment process for Indonesian Odoo users.

Odoo-Shopee Integration

In October, Odoo announced upcoming integration with Shopee, the leading eCommerce platform in Southeast Asia.

"The opening of Odoo's new office in BSD marks a significant milestone in our effort to penetrate the Indonesia market. Looking at our journey so far, I am also extremely proud of my team for their relentless contributions in helping our customers become more efficient, one app at a time. Moving forward, we aim to expand the team even more and the best part is: we are always looking for top talents to join us!"  — Benny Putra Sugito, Director of Odoo (Indonesia)

Odoo is committed to leading the Indonesian business scene. While its expansion also aims to generate employment opportunities to offer the country a professional workforce in tech and business management, Odoo is resolute in educating the market about the significance of utilizing the right business tools and is dedicated to offering a comprehensive and integrable yet approachable solution to facilitate an easy digital transformation process for 64.2 million businesses of all sizes in Indonesia.

About Odoo

Odoo is a Belgian online business management software with a complete suite of business modules. The open-source service provider operates in 19 locations worldwide, including Indonesia, the United States, Hong Kong SAR, and Dubai. With 80+ official apps and 49k+ third-party apps, Odoo manages businesses' finance, sales, inventory & manufacturing processes, human resources, marketing, team productivity, and more.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Belgian Unicorn Odoo Celebrates Remarkable First Anniversary in Indonesia

Belgian Unicorn Odoo Celebrates Remarkable First Anniversary in Indonesia